Skip to main content
. 2019 Oct 7;10(10):755. doi: 10.1038/s41419-019-1984-4

Fig. 1. Mutant IDH1 promotes erastin-induced ferroptosis.

Fig. 1

a IDH1R132C mutation promotes erastin-induced ferroptosis. HT-1080 cells with indicated IDH1 genotypes were treated with erastin (10 μM) for 12 h, and microscopically photographed. b Cell viability in (a) were assayed by trypan blue staining. c Endogenous 2-HG levels of HT-1080 cells with different IDH1 genotypes in (a) were determined by GC-MS. d Ferroptosis induction in HT-1080 cells. HT-1080 cells were treated with erastin, DFO, and Fer-1 as indicated for 12 h, and microscopically photographed. e Cell viability in (d) were assayed by trypan blue staining (n = 3; ****p < 0.0001 vs. DMSO group, Dunnett’s multiple comparisons test). f Expression of Flag-IDH1 or Flag-IDH1R132C in KYSE-170 cells were detected by Western blot. g IDH1R132C mutation promotes erastin-induced ferroptosis in KYSE-170 cells. KYSE-170 cells expressing Flag-IDH1 or Flag-IDH1R132C were treated with erastin for 16 h and cell viability was assayed by trypan blue staining (n = 3; ***p < 0.001 vs. EV group, Dunnett’s multiple comparisons test). h Pharmacological inhibition of mutant IDH1 reduces cells’ sensitivity to erastin. HT-1080 cells were treated with AG-120 or IDH-889 for 12 h, and then with erastin for additional 12 h. Cell viability were assayed by trypan blue staining (n = 3; **p < 0.01 and ***p < 0.001, Bonferroni’s multiple comparisons test)